CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,955,041 | +129.3% | 435,610 | +38.9% | 0.03% | +65.0% |
| Q2 2023 | $5,651,036 | -18.9% | 313,598 | -27.7% | 0.02% | -80.8% |
| Q1 2023 | $6,965,142 | -6.2% | 433,695 | +6.9% | 0.10% | -23.0% |
| Q4 2022 | $7,421,730 | +51.2% | 405,559 | +62.2% | 0.14% | +43.6% |
| Q3 2022 | $4,910,000 | +70.8% | 250,014 | +62.2% | 0.09% | +19.0% |
| Q2 2022 | $2,874,000 | -28.7% | 154,092 | -16.0% | 0.08% | -26.9% |
| Q1 2022 | $4,029,000 | +61.9% | 183,543 | +109.5% | 0.11% | +40.3% |
| Q4 2021 | $2,489,000 | +1355.6% | 87,608 | +624.0% | 0.08% | +600.0% |
| Q4 2020 | $171,000 | – | 12,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |